1. Introduction: Ionizing Radiation as a Therapeutic Tool
Radiotherapy is used in roughly half of all cancer patients at some point in their treatment. Its therapeutic principle is deceptively simple: deliver enough ionizing radiation to a target volume to destroy malignant cells while keeping the dose to critical normal tissue below the threshold of serious injury. Achieving this balance — the therapeutic ratio — is the central technical and biological problem of radiation oncology. This article reviews the physical and biological basis of external beam radiotherapy, the technologies that deliver it, the randomized evidence that defines its role, and the areas where evidence remains preliminary.
2. Physical and Biological Basis
2.1. Ionizing Radiation and DNA Damage
Ionizing radiation (X-rays, gamma rays, electrons, protons, ions) deposits energy in tissue, producing direct ionization and, indirectly, reactive oxygen species. The most consequential lesion is the DNA double-strand break, which, if unrepaired or misrepaired, leads to chromosomal aberrations, mitotic death, or apoptosis. Cells are most sensitive during mitosis and late G2; the differential radiosensitivity of tumors and normal tissues is exploited by fractionation.
2.2. The Biological «R’s» of Fractionation
Classical radiobiology attributes the benefit of fractionation to four processes, described by Withers and colleagues: repair of sublethal damage (normal tissue recovers between doses more efficiently than tumor), redistribution of cells into radiosensitive phases of the cycle, repopulation of surviving tumor cells (the rationale against unnecessarily long overall treatment times), and reoxygenation of hypoxic tumor regions that are relatively radioresistant. A fifth factor, intrinsic radiosensitivity, also varies between tumors.
2.3. Dose and the Therapeutic Ratio
Curative courses commonly deliver 60–70 Gy in 1.8–2 Gy fractions over weeks; palliative courses may use a single 8 Gy or short schemes. The relationship between dose and tumor control is sigmoid, as is the relationship between dose and normal-tissue complication. Modern practice manipulates both by conforming dose to the target and by selecting fractionation schedules on the basis of tumor biology and organ tolerance.
3. Technical Delivery
The last three decades have shifted radiotherapy from two-dimensional planning to volumetric, image-guided, intensity-modulated delivery.
- 3D conformal radiotherapy (3D-CRT) shapes beams to the target’s projection using multi-leaf collimators.
- Intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) modulate beam intensity across the field, sculpting concave dose distributions around critical structures.
- Image-guided radiotherapy (IGRT) uses on-board imaging (kV, cone-beam CT, MRI) before or during treatment to correct for setup and anatomical motion.
- Stereotactic body radiotherapy (SBRT/SABR) delivers very high doses per fraction with steep dose gradients, allowing ablation of small targets (for example, early lung tumors or oligometastases).
Together these technologies have expanded the range of tumors treatable with curative intent and reduced toxicity to adjacent organs.
4. Confirmed Clinical Evidence
4.1. Curative and Organ-Preserving Treatment
Radiotherapy alone or combined with systemic therapy is curative in many settings: early-stage laryngeal cancer (larynx preservation), locally advanced head and neck cancer, cervical cancer, prostate cancer, many skin cancers, and inoperable lung cancer. In breast cancer, whole-breast radiotherapy after breast-conserving surgery reduces local recurrence and has a modest effect on long-term survival in certain risk groups (supported by large randomized trials and meta-analyses).
4.2. Chemoradiation
Concurrent chemoradiotherapy improves survival or local control relative to radiotherapy alone in several diseases, including locally advanced cervical cancer and head and neck cancer. This reflects radiation sensitization and, in some tumors, a systemic effect. The combination increases acute toxicity and requires careful multidisciplinary selection.
4.3. Palliative Radiotherapy
Radiotherapy is highly effective for palliating painful bone metastases, bleeding, obstruction, and brain metastases. Randomized evidence shows that a single 8 Gy fraction provides pain relief comparable to more prolonged courses in uncomplicated bone metastases, making it a standard option.
4.4. SBRT for Early-Stage Lung Cancer
For medically inoperable early-stage non-small cell lung cancer, SBRT achieves high rates of local control in prospective trials, establishing it as the standard alternative to surgery. The pivotal trial by Timmerman and colleagues (RTOG 0236) reported excellent local control with a three-fraction regimen.
5. Early Research and Emerging Approaches
Several areas are promising but not yet established:
- FLASH radiotherapy delivers dose at ultra-high rates and has shown reduced normal-tissue damage in preclinical models while maintaining tumor control. First-in-human treatments have been reported, but this remains early clinical research with limited follow-up.
- Combination with immunotherapy (radioimmunotherapy). Radiotherapy can induce immunogenic cell death and may act as an immunomodulator. Randomized trials in several diseases have shown that adding immune checkpoint inhibitors to radiotherapy improves some endpoints, but the optimal sequencing, volume, and patient selection are not settled.
- Hypofractionation and extreme hypofractionation reduce the number of visits. This is established in prostate and breast cancer, but the appropriateness for other sites and its late-toxicity profile require continued follow-up.
6. Toxicity and Limitations
Radiotherapy is a local therapy with local consequences. Acute effects (mucositis, dermatitis, fatigue) and late effects (fibrosis, xerostomia, radiation pneumonitis, enteritis/proctitis, neurocognitive effects after whole-brain radiation) vary by site and dose. A small but real increase in secondary malignancy is documented, particularly for long-term survivors treated at a young age. These risks are the reason for continual dose and volume reduction.
7. Unresolved Questions and Speculative Directions
- Can radiotherapy be used to treat all metastatic sites (abscopal/oligometastatic strategies) and produce durable regression elsewhere through immune activation? The abscopal effect is documented but rare and unpredictable; population-level benefit from treating all sites is not established.
- Can molecular radiosensitivity predictors individualize fractionation? Candidate gene expression classifiers exist but are not yet standard; prospective validation is incomplete. [Marked for verification.]
8. Conclusion
External beam radiotherapy is a mature, evidence-based cancer treatment whose modern form is volumetric, image-guided, and highly conformal. It is curative in many localized and locally advanced cancers, highly effective in palliation, and increasingly combined with systemic therapy. Its principal limitations are anatomical (proximity to critical organs), biological (radioresistance of some tumors and hypoxia), and long-term (late toxicity and second malignancy). Emerging technologies such as FLASH and radiogenomic selection are promising but remain in early stages and should not yet be presented as established practice.
Sources and Key Research Centers
- National Cancer Institute — patient and professional resources on radiation therapy.
- American Society for Radiation Oncology (ASTRO) — clinical guidelines, model policies, and the evidence base for radiotherapy.
- European Society for Radiotherapy and Oncology (ESTRO) — European guidance and educational resources.
- International Atomic Energy Agency (IAEA) — global radiotherapy infrastructure and safety standards.
- SBRT for early-stage lung cancer
- Timmerman R, Paulus R, Galvin J, et al. «Stereotactic body radiation therapy for inoperable early stage lung cancer.» JAMA, 2010; 303(11): 1070–1076. DOI: 10.1001/jama.2010.261
- Radiobiology of fractionation
- Withers HR. «The four R’s of radiotherapy.» Advances in Radiation Biology, 1975; 5: 241–271. [Bibliographic details should be verified.]
- ClinicalTrials.gov — ongoing trials of FLASH radiotherapy, stereotactic dose escalation, and radioimmunotherapy (search terms: FLASH radiotherapy, SBRT, radiotherapy plus immunotherapy).
Note: citation identifiers are provided where available; readers should confirm bibliographic details against the publisher’s record. This article is an editorial scientific overview and is not a medical recommendation.